One of the standout features of modular cleanrooms is flexibility. These are not fixed, concrete investments you’re stuck with. Need to reconfigure your workflow? Expand your space? Move to a new site? No problem. Mobile and modular cleanrooms are designed to shift with your strategy.

For companies working in fast-moving areas of biomanufacturing, where processes change, pipelines shift, and speed matters, this kind of adaptability can be a game-changer.

Planning for growth can feel like a gamble. Build too much, and you’ve tied up capital in unused space. Build too little, and you risk bottlenecks when demand spikes. Modular cleanrooms eliminate that guesswork.

Start small. Scale fast. These systems are prefabricated and easy to expand, meaning your cleanroom footprint can grow when, and only when, you need it to. Scaling up can be done incrementally and with minimal disruption.

Traditional cleanrooms are expensive to build and impossible to move. When you leave a site or outgrow your facility, that cleanroom doesn’t come with you—it stays behind, along with the capital you have sunk into it.

Mobile and modular cleanrooms, on the other hand, are designed to be portable. For example, a BSL-3 cleanroom facility in Singapore was successfully relocated (across the island) after a decade of use, continuing operations in a new location with minimal downtime. The system continued operating, just in a new location, without skipping a beat. This kind of mobility can extend the useful life of the infrastructure and preserve capital investment.

At the end of the day, modular cleanrooms give you options. They’re fast to deploy, easy to adapt, and designed to scale with you, not work against you. Whether you’re ramping up, shifting production, or relocating your entire operation, you have a cleanroom that moves with you—not one that holds you back.

Explore Germfree’s mobile and modular cleanroom solutions here to see how your biomanufacturing operations can gain flexibility and scale.

Without a standardized setup, no two technicians work the same way. Small differences in preparation, verification, or documentation can quickly accumulate, introducing inconsistencies that jeopardize patient safety. In high-volume environments, even minor variations can have a big impact, creating unnecessary stress for staff and risk for patients. 

Another challenge is equipment inefficiency. Critical tools such as scales, barcode scanners, printers, or cameras are often positioned outside the sterile field. Technicians must repeatedly step away from the compounding area to access these devices, slowing the process, breaking the sterile field, and increasing the risk of contamination. These small interruptions can compound over time, reducing both efficiency and safety. 

Process interruptions are a related concern. Switching between multiple devices forces technicians to stop, refocus, and often reestablish aseptic technique. These interruptions make it difficult to maintain a consistent flow, increase cognitive load, and raise the chance of mistakes. Collectively, these challenges create friction in the workflow, making precise and reliable compounding harder than it should be. 

Current IV compounding setups often suffer from cluttered workspaces.

Smarthood captures precise photos with integrated cameras.

Standardization is more than a workflow convenience, it is a safety imperative. When every technician follows the same sequence using the same tools, the risk of error is significantly reduced. Processes become repeatable, predictable, and measurable, which strengthens compliance with USP <797> and <800> requirements.

Reducing variability also enhances aseptic technique. Fewer steps outside the sterile field and fewer touchpoints allow technicians to maintain focus, concentration, and precision for longer periods. Standardization removes guesswork from compounding, ensuring uniform quality control across all staff and shifts.

Facilities using Smarthood report measurable improvements. Compounding times decrease because technicians no longer need to leave the sterile field. Workflow interruptions are minimized, resulting in smoother processes and fewer opportunities for contamination.

Staff satisfaction improves as well: the organized, ergonomic setup reduces physical strain and cognitive stress, allowing technicians to work confidently and consistently. Feedback from facilities consistently emphasizes one theme: Smarthood removes friction from the IV compounding process, making it safer, faster, and more predictable for both staff and patients.

Smarthood is currently streamlining pharmacy operations at Ballad Health. Hear directly from the team about their experience here.

Ready to standardize your IV workflow? Learn more about Smarthood here.

Artificial intelligence opens the door to more dynamic, responsive isolator environments. Rather than operating on static logic, isolators could learn from patterns, respond to sensor data, and optimize internal workflows— minimizing contamination risks and reducing downtime.

Imagine an isolator where internal movements—whether robotic, operator-assisted, or semi-automated—are optimized in real time by AI. This goes beyond basic programming. Intelligent path planning could adapt to shifting conditions inside the chamber: avoiding areas recently exposed to higher particulate levels, dynamically adjusting movements to prevent cross-contamination, and predicting the most efficient task flow based on the current process stage.

AI could also support closed-loop decontamination strategies by analyzing activity patterns inside the isolator and initiating targeted cleaning cycles only when—and where—they’re needed. This approach could reduce downtime, preserve resources, and extend the operational readiness of the system.

At Germfree, we design and manufacture custom isolators for pharmaceutical, healthcare, and biocontainment applications. While our isolators do not currently include AI systems, we’ve worked alongside organizations that are taking meaningful steps toward this future—integrating robotics and automation into aseptic environments in ways that align with AI’s potential.

The integration of AI into isolator design is still emerging, but the groundwork is here. With intelligent motion planning, behavior modeling, and predictive system control, isolators may soon become more than static containment systems—they could become collaborative tools that anticipate and respond to the needs of modern aseptic workflows.

Read the complete August 2025 issue of Life Sciences Insights here.

Pharma must embrace lessons from industries where companies have built global networks capable of delivering consistent experiences and products across borders. Can we translate the operational excellence seen in fast food franchises, consumer packaging, or even aerospace manufacturing into pharmaceutical production? We must build a smarter, more agile pharmaceutical supply chain that meets patient needs in real time, without compromising on quality or safety.

We propose a model of pharmaceutical manufacturing that draws on proven methodologies from outside our industry and uses them to reimagine the way we make and deliver medicines.

By integrating distributed manufacturing, standardized kitting, big data, and intelligent automation, we believe the future of pharma can be increased patient access through faster, more efficient, and more reliable processes for everyone.

Kitting has transformed logistics in other industries, and offers a proven strategy for achieving operational consistency across varied settings.^2,3 Companies like IKEA and HelloFresh have mastered the art of distributing standardized kits that produce consistent results in wildly different environments. Despite perceived differences in complexity, pharma can achieve similar reproducibility in drug production.⁴ Single-use systems and cell and gene therapy workflows have already embraced the early stages of this approach. Now, it’s time to expand and industrialize the model.

Incorporating kitting into pharma at scale opens the door to rapid deployment of modular manufacturing units. Each kit becomes a controlled building block, simplifying training, reducing the margin for error, and minimizing dependency on centralized infrastructure. Critically, well-designed kitting strategies enhance supply chain resilience by allowing for multi-supplier sourcing and eliminating single points of failure. This approach helps prevent production delays and reduces the risk of stockouts, ensuring consistent availability of essential components.

Figure 1 shows a sample pharma kitting process that can links suppliers, facilities, and operators into a harmonized system. It would transform a diverse, multi-supplier supply chain into a replicable, standardized building block, enabling reliable performance at every node in the network.

First, components such as reagents, excipients, consumables, and disposables are sourced from pre-qualified suppliers based on specifications tailored to the kit’s intended application. Each item is then inspected, serialized and matched against a bill of materials. The components are then assembled into standardized kits in a GMP-compliant kitting facility following validated SOPs. This process includes packaging, labeling and quality checks to ensure every kit is complete, traceable, and compliant. Finalized kits are then queued for distribution to network nodes, where they can be deployed interchangeably without requiring local revalidation, reducing complexity and accelerating readiness.

To successfully build upon the flexibility introduced by kitting, standardized operational models are essential to ensure uniform quality and performance. Borrowing from the franchise systems used in the food industry, pharmaceutical operations can streamline deployments while preserving compliance and reliability.

Chipotle brings new restaurants online in months, not years, with systems thinking, as shown in Figure 2. Each location follows strict procedures, uses similar layouts and tools, and delivers a reliably consistent product. ^5,6

Contrast this with traditional pharma manufacturing, where each site is often a bespoke project requiring years of design, construction, validation, and tech transfer. The opportunity here is obvious: if we can build sites that are replicable like franchises, we can dramatically reduce launch timelines and costs.

Done right, it unlocks the potential to clone successful production environments repeatedly, no matter the geography or scale.⁷

To fully realize this standardization and enhance traceability, advanced technologies must be integrated into every step of the manufacturing process. RFID and machine vision enable real-time oversight, ensuring each component is verified and every action is captured for analysis and accountability.

Hospitals already leverage RFID tagging in crash carts to monitor medication availability in real time, ensuring lifesaving supplies are always in the right place at the right time. ^8,9 In pharma manufacturing kits, RFID tags could track components from supplier to end-use, flag inconsistencies, and automate inventory reordering.

Machine vision offers real-time compliance monitoring—ensuring every action by every operator matches protocol, detecting deviations long before they lead to batch failures. Several companies such as Nestle,¹⁰ Pepsi,¹¹ and Amazon¹² have implemented computer vision tools for enhancing efficiency, compliance, and adherence to safety guidelines. We too can adopt tools for product inspection, label reading, process quality and operator compliance.

Together, these tools reduce manual error, enhance traceability, and create a digital thread of accountability across the entire process. This level of transparency and accuracy equate to a higher-quality product for patients in this new paradigm.

A truly agile, distributed pharmaceutical network cannot operate without a comprehensive, data-centric core.¹³ Operational awareness across all nodes tracking not just equipment performance but also material movement, production status, and operator behavior is critical not only for patient safety and regulatory compliance but also for proactive supply chain management.¹⁴ Companies like Walmart and Amazon have invested heavily in predictive analytics and bid data models.

A well-integrated data infrastructure for them enables predictive inventory management, reducing the risk of product expiration and minimizing waste across the network.^15,16 It can help forecast material needs, reroute supplies in response to regional demand, and even automate replenishment processes. Applied to the pharmaceutical industry, machine learning algorithms, fueled by large, high-quality datasets, can serve as early warning systems for impending drug shortages, enabling intervention before patients are affected.¹⁵

Standardized kits and harmonized facility design make it possible to move materials and workloads between nodes with minimal disruption—removing the traditional barriers posed by variations in equipment, SOPs, and staff training. In such a system, key performance indicators (KPIs) including rejection rates, customer complaints, recall frequency, and turnaround time can be continuously monitored and benchmarked across the network.¹⁶ This enables swift identification of performance anomalies and facilitates ongoing optimization of both processes and resource allocation.

Metrics such as rejection rates and recall frequency provide visibility into what went wrong, but understanding how and why deviations occur requires taking a closer look at the execution of the process itself. We want to embrace Quality by Design (QbD) principles.¹⁷ QbD emphasizes that quality should be built into a process from the outset, not tested in at the end. This QbD philosophy will be built into our processes and guaranteed by our MES and machine vision platforms.

The integration of predictive analytics in concert with real-time cross-site visibility under the QbD paradigm is what sets a modern, distributed network apart from traditional manufacturing. These tools lay the foundation for the next critical element: a quality and compliance strategy that is as adaptive, scalable, and intelligent as the network it governs.

While distributed manufacturing offers speed, flexibility, and proximity to patients, it also introduces a broader array of variables that, if left unchecked, can pose serious risks to quality. With multiple sites, multiple operators, and dynamic supply chains, the challenge lies in ensuring that every product meets the same high standard, regardless of where or by whom it was made.

However, this complexity can be managed through the rigorous standardization and system integration we have discussed above. By unifying kit design, facility layouts, equipment, and process workflows, and coupling them with a manufacturing execution system (MES) and advanced machine vision capabilities, we can build a foundation of uniformity. These digital and physical systems together generate structured data that feeds into a distributed quality management system (QMS), providing real-time oversight and traceability across every node of the network.

Maintaining regulatory integrity across a distributed model requires intentional system design and robust oversight mechanisms. Quality management systems must evolve to support decentralized operations while satisfying diverse state and federal requirements.

A distributed network doesn’t mean sacrificing quality or compliance, it means designing for it from the ground up. This starts with a distributed quality management system (QMS) tightly integrated with the manufacturing execution system (MES). By integrating data from multiple nodes, including environmental controls, MES workflows, and inventory status; operators and quality teams can detect early warning signs of disruptions such as drug shortages (e.g., dexmedetomidine) and ensure site-level compliance. The system’s centralized logic enables predictive oversight while preserving local autonomy, reinforcing the critical role of a data-driven QMS in a decentralized model. All can be visualized from a single live dashboard, such as the one in Figure 3.

Each operator follows the same guided workflow. Each sensor feeds into a centralized monitoring system. Each anomaly triggers an immediate response, not a days-later deviation report. Packaging solutions that double as a storage container and an in-process mixing vessel can further simplify the process. Like Nespresso and Keurig pods in a controlled just-add-water approach, shelf-stable packaging will be created and filled at the centralized kitting locations (blue nodes Figure 1) and shipped to respective green nodes, where they will await demand for the medicine. Once demand is triggered, the packaging can then be formulated and translated directly into a patient-ready medicine.

Compliance for a distributed network with this packaging concept must be multi-jurisdictional.¹⁸ With oversight from both the FDA and state pharmacy boards, each node must always be audit-ready. This demands real-time data capture, electronic batch records, and a culture that embraces transparency.

While the distributed model offers compelling advantages in scalability, flexibility, and resilience, it is not without supply, logistics, workforce, and infrastructure challenges. These underscore the need for deliberate system design, robust digital infrastructure, and continuous investment in training and supplier management.

As distributed manufacturing matures, its alignment with sustainability and rapid deployment goals becomes increasingly evident. Innovations in automation, prefabricated infrastructure, and localized production will redefine what is possible in pharmaceutical supply chains. This model also opens doors to faster, more sustainable production. Modular cleanrooms are already available that can be prefabricated and deployed in weeks. Automation and robotics reduce the need for high-intensity labor. Environmental sensors ensure every site meets GMP conditions,¹⁸ regardless of climate or location. Perhaps most exciting is the potential to localize production. A network of nimble, tech-enabled manufacturing sites could respond to local outbreaks, address regional drug shortages, or even adapt formulations to community-specific needs, all without waiting on global supply chains.

The pharmaceutical industry can no longer afford to view manufacturing as a fixed, centralized process. In an era that demands agility, responsiveness, and resilience, a new model is emerging; one shaped by lessons from other industries that have mastered scale and consistency. By adopting distributed manufacturing, embracing intelligent kitting, and building a digital backbone of data and automation to serve predictive analytics models,¹⁹ we can transform how medicines are made and delivered. This intentional, technology-enabled design turns a potential risk into a strategic advantage, laying the groundwork for resilient, compliant, and continuously improving manufacturing operations at scale.

It’s not just a matter of efficiency—it’s a matter of equity. Because patients everywhere deserve better. And now, we have the tools to deliver it.

Pharmaceutical Manufacturing and Packing Sourcer, Summer 2025, pages 43-47. © Samedan Ltd.

1. Mascia, S. et al. (2020). “End-to-End Continuous Manufacturing of Pharmaceuticals.” Annual Review of Chemical and Biomolecular Engineering.
2. IKEA Supply Chain Strategy, IKEA Annual Sustainability Report (2023).
3. Smith, D. (2021). “How Meal-Kit Services Changed the Supply Chain.” Supply Chain Management Review.
4. Hellström, D., & Nilsson, F. (2011). “Logistics-Driven Packaging Innovation.” International Journal of Physical Distribution & Logistics Management.
5. Chipotle Mexican Grill, Inc. (2023). Annual Report.
6. Mena, C., et al. (2014). “Standardization vs Customization in Supply Chain Management.” Journal of Operations Management.
7. McKinsey & Company (2021). “Big Data Analytics in Pharmaceutical Manufacturing.”
8. Sarac, A., Absi, N., & Dauzère-Pérès, S. (2010). “A Literature Review on the Impact of RFID Technologies on Supply Chain Management.” International Journal of Production Economics.
9. GS1 Healthcare (2022). “RFID Implementation for Inventory Management.” GS1 Healthcare Reference Book.
10. Nestlé AI Scoop Detection. (2022). Vision Systems Design. https://www.vision-systems.com/factory/consumer-packaged-goods/article/14299012/nestle-automates-inspection-of-plastic-scoops-in-adult-nutrition-products
11. Suntory PepsiCo Date Verification. (2023). Insight.tech. https://www.insight.tech/industry/machine-vision-inspection-puts-the-focus-on-quality-control
12. Amazon Worker Monitoring with Machine Vision. (2020). Ars Technica. https://arstechnica.com/information-technology/2020/12/amazon-to-roll-out-tools-to-monitor-factory-workers-and-machines
13. Capgemini (2022). “Leveraging Big Data for Pharmaceutical Logistics Optimization.”
14. Chui, M., Manyika, J., & Miremadi, M. (2018). “What AI Can and Can’t Do (Yet) for Your Business.” Harvard Business Review.
15. ISPE (2021). “Pharma 4.0: Data Integrity by Design.”
16. Wang, Y., et al. (2020). “Predictive Analytics in Pharmaceutical Supply Chains.”
17. Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, Woodcock J. Understanding pharmaceutical quality by design. AAPS J. 2014 Jul;16(4):771-83.
18. WHO (2019). “Good Manufacturing Practices for Pharmaceutical Products.”
19. Stank, T. P., et al. (2019). “Predictive Analytics and Supply Chain Performance.” Journal of Business Logistics.

In the interview, Carol explains that several recent executive orders are reshaping the landscape for pharmaceutical production in the US. There is a strong governmental push to increase domestic manufacturing capacity to reduce reliance on foreign supply chains. This surge in demand exposes critical gaps in infrastructure; gaps that Germfree is uniquely positioned to fill. Our modular and mobile cleanroom units provide flexible, scalable solutions designed for rapid deployment, enabling manufacturers to respond quickly to sudden capacity needs.

One of the key initiatives Carol highlights in the interview is the ongoing modernization of the Strategic National Stockpile, originally set in motion by a prior administration. This aims to diversify the supply chain and reduce vulnerabilities, such as the 2024 hurricane that severely disrupted IV solution supplies when 40% of hospitals depended on a single supplier, Baxter. Germfree’s ability to deliver quick surge capacity cleanrooms plays a vital role in mitigating such risks.

Carol also emphasizes the growing need for digital integration and automation in cleanroom environments to meet heightened regulatory standards. For example, our collaboration with On Demand Pharmaceuticals (ODP) at North Mississippi Medical Center allowed us to pilot mobile cleanroom technology that directly supports these compliance needs while providing operational flexibility.

Through this interview, Carol provides a transparent look at how Germfree continues to innovate — balancing rapid response with rigorous cleanroom regulatory compliance — to serve the evolving life sciences industry and help secure the nation’s pharmaceutical infrastructure.